• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CytoVale, Pareto Biotechnologies receive grants from Breakout Labs

CytoVale, Pareto Biotechnologies receive grants from Breakout Labs

November 18, 2013
CenterWatch Staff

Breakout Labs, a program of the Thiel Foundation, has announced its support of two new early-stage companies leveraging cell-based technologies: CytoVale and Pareto Biotechnologies. The new grants bring the total number of companies supported by Breakout Labs to 16.

CytoVale, an alum of the QB3 Startup in a Box program, is pioneering a new class of biomarkers based on the mechanical properties of individual cells, or mechanomics. Disease states dramatically alter cells' physical properties. Using microfluidics to route and physically probe individual cells, CytoVale can measure over 10 biophysical cell markers at rates above 2,000 cells per second, providing a high-throughput, low-cost method of detecting disease.

CytoVale CEO Ajay Shah, Ph.D., and co-founder Dino Di Carlo, Ph.D., a UCLA professor, have targeted the early detection of sepsis as an initial application of their technology. Current standard of care identifies septic patients after organ damage has begun, so there is a clear need for rapid, accurate and cost-effective methods of detecting sepsis at the earliest stages of the infection.

Shah and Di Carlo recently presented their mechanomics platform, consisting of a bench-top instrument and disposable disease-specific sample cartridges, at the annual Breakout Labs Unboxing event. Unboxing is Breakout Labs' invitation-only demonstration day at which companies supported by the program present their latest research and technologies to an esteemed group of investors, scientists and entrepreneurs. "We have already made valuable connections through the Breakout Labs network that will likely be key to our next phases of commercialization," said Shah.

Utilizing polyketide pathways and auxiliary technologies, Pareto Biotechnologies' platform creates designer molecules with near-term applicability in cosmetics, flavors and fragrances, currently derived from either limited natural resources or petroleum. Pareto's technology will enable production of similar molecules at a lower price point in a more environmentally sustainable manner than current production methods allow, while still retaining the designation of "natural."

Pareto's CEO, Jamie Bacher, Ph.D., is a synthetic biologist who previously managed a $100 million project at Total New Energies in partnership with Amyris. Pareto's co-founders include Joe Noel, Ph.D., who worked with the biochemistry and application of plant secondary metabolism; Mike Mendez, inventor of the XenoMouse and founder of four biotech startups including Sapphire Energy; and Mike Burkart, Ph.D., who has experience with polyketide and fatty acid synthases and metabolic engineering.

"Synthetic biology is an area of substantial technological interest to us," said Hemai Parthasarathy, Breakout Labs' scientific director. "There is obviously breakthrough potential for companies that have both a deep understanding of biology and the savvy to navigate biotech's significant business development hurdles."

Over the past two years, Breakout Labs has matured into a new model for early-stage R&D funding. Grant recipients benefit not only from financing at a tipping point in their technical development, but also gain access to an ever-broadening network of investors, entrepreneurs and startup resources that are needed for long-term sustainability of their companies.

"Having worked intensively with our first companies, we have honed the support that is most critical to their development," said Lindy Fishburne, Breakout Labs executive director. "In addition to our semi-annual networking and mentoring events in the Bay Area, we have been able to make introductions and provide strategic advice throughout the year.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing